Cyntegrity streamlines risk-based quality management in clinical trials

Cyntegrity, a German technology firm, has enhanced risk-based quality management for pharmaceutical clinical trials through strategic use of Microsoft Azure cloud technologies. Faced with challenges stemming from large, disparate, and error-prone data sources, Cyntegrity implemented a cloud-native solution to harmonize, analyze, and safeguard sensitive trial data. Their software-as-a-service (SaaS) platform, MyRBQM Portal, now integrates multiple Azure services for scalable, secure, and compliant trial data processing. The migration delivered high system availability, improved scalability, dramatically reduced IT costs, and allowed the company to expand internationally while maintaining strict regulatory compliance. Azure App Service, Azure Functions, Azure Active Directory, and Microsoft Defender for Cloud underpin the new technical architecture. Resource pools are configured per study, with data residency features ensuring privacy for each region. The scalable architecture enables the simultaneous processing of hundreds of trials, offers proactive risk anomaly detection, and ensures customers are alerted early to quality issues. The platform anonymizes sensitive data, automates risk monitoring, and provides user-facing dashboards for operational transparency. This structure gives pharmaceutical and biotech clients a reliable, compliant, and cost-effective solution for global study management, reducing manual IT overhead and error risk. Cyntegrity reports 99.9% uptime and the flexibility to handle rapid customer growth and increasing study loads. Operational transparency is further enabled by integrating Azure DevOps into the full lifecycle across customer support, change management, and quality assurance, aligning with evolving market and regulatory requirements. The MyRBQM Portal's first innovation is self-service resource configuration and near real-time performance insight for trial sponsors. Ultimately, the solution positions Cyntegrity to further leverage AI and analytics in the future, fostering faster drug development by enabling high-quality, compliant, and agile clinical research management.